Bio News
Alnylam Pharmaceuticals cut its revenue forecast for TTR therapies, including Amvuttra, by $200 million, wiping $12 billion from its market value. The reduction was attributed to normalized potential demand, while quarterly revenue of $1.01 billion fell short of expectations. Concerns are growing in the increasingly competitive TTR cardiomyopathy market, and the presentation of data from the failed eplontersen study at the end of August is expected to add further uncertainty.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
